NasdaqGS:IDYABiotechs
Will IDEAYA’s (IDYA) IDE892 Combo Strategy in MTAP‑Deleted Cancers Reshape Its Targeted Oncology Narrative?
Earlier this week, IDEAYA Biosciences announced that it has begun Part 2 monotherapy expansion in its Phase 1/2 trial of IDE892, a highly selective PRMT5 inhibitor for MTAP-deleted solid tumors including non-small cell lung cancer and pancreatic ductal adenocarcinoma, at exposures expected to provide 24‑hour EC90 target coverage.
An interesting element of this update is IDEAYA’s plan to position IDE892 as a combination backbone across MTAP-deleted cancers, including collaborations with...